U.S. markets close in 2 hours 44 minutes
  • S&P 500

    3,274.67
    +28.08 (+0.86%)
     
  • Dow 30

    26,968.70
    +153.26 (+0.57%)
     
  • Nasdaq

    10,823.59
    +151.32 (+1.42%)
     
  • Russell 2000

    1,467.02
    +15.20 (+1.05%)
     
  • Crude Oil

    40.19
    -0.12 (-0.30%)
     
  • Gold

    1,867.20
    -9.70 (-0.52%)
     
  • Silver

    23.12
    -0.07 (-0.31%)
     
  • EUR/USD

    1.1625
    -0.0050 (-0.43%)
     
  • 10-Yr Bond

    0.6580
    -0.0080 (-1.20%)
     
  • GBP/USD

    1.2706
    -0.0046 (-0.36%)
     
  • USD/JPY

    105.6200
    +0.2180 (+0.21%)
     
  • BTC-USD

    10,659.35
    -101.24 (-0.94%)
     
  • CMC Crypto 200

    227.19
    +9.36 (+4.30%)
     
  • FTSE 100

    5,842.67
    +19.89 (+0.34%)
     
  • Nikkei 225

    23,204.62
    +116.80 (+0.51%)
     

Satsuma Pharmaceuticals to Present at the 9th Annual SVB Leerink Global Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Feb. 18, 2020 (GLOBE NEWSWIRE) -- Satsuma Pharmaceuticals, Inc. (STSA) a clinical-stage biopharmaceutical company, today announced that John Kollins, President and Chief Executive Officer, will present a corporate update at the 9th Annual SVB Leerink Global Healthcare Conference on February 25, 2020 in New York City.

9th Annual SVB Leerink Global Healthcare Conference

Date: 

 

Tuesday, February 25th, 2020

Time: 

 

11:30am Eastern Time

Location: 

 

Lotte New York Palace Hotel, The Apartment Room, 4th Floor

Webcast:

 

Webcast Link

A live audio webcast of the presentation will be accessible on the Events page of the Investors section on the Company’s website at www.satsumarx.com. The webcast replay will be available approximately two hours after the presentation ends and will be accessible for 90 days.

About Satsuma Pharmaceuticals and STS101
Satsuma Pharmaceuticals is a clinical-stage biopharmaceutical company developing a novel therapeutic product for the acute treatment of migraine, STS101. STS101 is a drug-device combination of a proprietary dry-powder formulation of dihydroergotamine mesylate (DHE), which can be quickly and easily self-administered with a proprietary pre-filled, single-use, nasal delivery device. In developing STS101, Satsuma has applied proprietary nasal drug delivery, dry-powder formulation, and engineered drug particle technologies to create a compact, simple-to-use, non-injectable DHE product that can be rapidly self-administered in a matter of seconds. The Company believes STS101 would, if approved, be an attractive migraine treatment option for many patients and may enable a larger number of people with migraine to realize the long-recognized therapeutic benefits of DHE therapy. STS101 has undergone extensive pre-clinical development, completed a Phase 1 clinical trial, and is currently in Phase 3 development.

Satsuma is headquartered in South San Francisco, California with operations in both California and Research Triangle Park, North Carolina. For further information, please visit www.satsumarx.com.

INVESTOR AND CORPORATE CONTACTS:            

Corey Davis, PhD
LifeSci Advisors, LLC
cdavis@lifesciadvisors.com

Tom O’Neil, Chief Financial Officer
Satsuma Pharmaceuticals, Inc.
tom@satsumarx.com